KalVista Pharmaceuticals (KALV) News Today $13.10 -0.45 (-3.32%) Closing price 04:00 PM EasternExtended Trading$12.96 -0.14 (-1.03%) As of 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Susquehanna Fundamental Investments LLC Takes $680,000 Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Susquehanna Fundamental Investments LLC acquired a new position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 80,319 shares ofMay 5 at 4:32 AM | marketbeat.comAllostery Investments LP Purchases Shares of 479,100 KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Allostery Investments LP acquired a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 479,100 shares of the specialty pharmaceutical company's stock, vaMay 4 at 7:45 AM | marketbeat.comBoxer Capital Management LLC Purchases New Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Boxer Capital Management LLC bought a new stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,590,000 shares of the specialMay 4 at 6:25 AM | marketbeat.comMarshall Wace LLP Purchases 103,072 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Marshall Wace LLP boosted its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 691.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 117,978 shares of the specialty phMay 3 at 3:47 AM | marketbeat.comAdage Capital Partners GP L.L.C. Lowers Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Adage Capital Partners GP L.L.C. decreased its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 78.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 300,000 shares of the speciaMay 2 at 4:46 AM | marketbeat.comEmerald Mutual Fund Advisers Trust Has $4.66 Million Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Emerald Mutual Fund Advisers Trust cut its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 15.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 549,688 shares of the specialty pharmaceutical company's stock after sellinMay 1, 2025 | marketbeat.comXTX Topco Ltd Makes New $267,000 Investment in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)XTX Topco Ltd bought a new stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 31,573 shares of the specialty pharmaceutical compaApril 28, 2025 | marketbeat.comSilverarc Capital Management LLC Has $5.19 Million Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Silverarc Capital Management LLC raised its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 6.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 612,173 shares of the specialty pharmacApril 24, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Trading Up 5.9% - Still a Buy?KalVista Pharmaceuticals (NASDAQ:KALV) Shares Up 5.9% - Here's What HappenedApril 23, 2025 | marketbeat.comWalleye Capital LLC Invests $2.27 Million in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Walleye Capital LLC bought a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 267,743 shares of the specialty pharmaceuticApril 21, 2025 | marketbeat.comVanguard Group Inc. Acquires 104,716 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Vanguard Group Inc. grew its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 4.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,255,243 shares of the specialty pharmaceutical companyApril 19, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Rating of "Buy" by BrokeragesKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) has been assigned a consensus rating of "Buy" from the eight brokerages that are covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy reApril 18, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by American Century Companies Inc.American Century Companies Inc. trimmed its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 71.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,072 sApril 16, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Buys $235,500.00 in StockApril 12, 2025 | insidertrades.comKalVista: Poised For Rare Disease TransformationApril 12, 2025 | seekingalpha.comKalVista Pharmaceuticals (NASDAQ:KALV) Trading Down 7.2% - Here's What HappenedKalVista Pharmaceuticals (NASDAQ:KALV) Shares Down 7.2% - Here's WhyApril 10, 2025 | marketbeat.comKalVista Pharmaceuticals' (KALV) Buy Rating Reiterated at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Tuesday.April 10, 2025 | marketbeat.comKalVista subsidiary licenses commercialization rights for sebetralstat in JapanApril 9, 2025 | markets.businessinsider.comKalVista Pharmaceuticals (NASDAQ:KALV) Shares Up 8.3% - Should You Buy?KalVista Pharmaceuticals (NASDAQ:KALV) Shares Up 8.3% - Still a Buy?April 9, 2025 | marketbeat.comKalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in JapanApril 8, 2025 | uk.finance.yahoo.comKalVista licenses commercialisation rights for HAE to Kaken in JapanApril 8, 2025 | finance.yahoo.comKalVista rises after licensing deal with Kaken for lead asset in JapanApril 8, 2025 | msn.comSchroder Investment Management Group Acquires 374,213 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Schroder Investment Management Group grew its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 86.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 805,445 shares of the specialty pharmaceutical company's stock afterApril 6, 2025 | marketbeat.comKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 | businesswire.comKalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | businesswire.comQ4 Earnings Forecast for KALV Issued By Leerink PartnrsKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Equities research analysts at Leerink Partnrs issued their Q4 2025 EPS estimates for shares of KalVista Pharmaceuticals in a note issued to investors on Tuesday, March 25th. Leerink Partnrs analyst J. Schwartz forecasts that the specialMarch 29, 2025 | marketbeat.comKalVista completes enrollment in KONFIDENT-KID clinical trial of sebetralstatMarch 27, 2025 | markets.businessinsider.comKalVista Pharmaceuticals (NASDAQ:KALV) Given Buy Rating at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Wednesday.March 27, 2025 | marketbeat.comStifel Nicolaus Keeps Their Buy Rating on KalVista Pharmaceuticals (KALV)March 27, 2025 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on KalVista Pharmaceuticals (KALV)March 27, 2025 | markets.businessinsider.comKalVista Pharmaceuticals (NASDAQ:KALV) Earns "Buy" Rating from Jones TradingJones Trading restated a "buy" rating and issued a $30.00 price objective on shares of KalVista Pharmaceuticals in a report on Wednesday.March 27, 2025 | marketbeat.comKalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trialMarch 26, 2025 | finance.yahoo.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Recommendation of "Buy" by AnalystsKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) has been assigned an average recommendation of "Buy" from the seven brokerages that are currently covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating and one has issued a strong bMarch 23, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 3% - Here's WhyKalVista Pharmaceuticals (NASDAQ:KALV) Shares Down 3% - Time to Sell?March 20, 2025 | marketbeat.comKalVista Pharmaceuticals' (KALV) Buy Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday.March 15, 2025 | marketbeat.comKalVista Pharmaceuticals' (KALV) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Thursday.March 14, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Releases Earnings Results, Misses Estimates By $0.03 EPSKalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) issued its earnings results on Wednesday. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.03).March 13, 2025 | marketbeat.comInsider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells 6,669 Shares of StockKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin L. Palleiko sold 6,669 shares of the company's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $11.97, for a total transaction of $79,827.93. Following the transaction, the chief executive officer now directly owns 287,811 shares of the company's stock, valued at $3,445,097.67. This represents a 2.26 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.March 11, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 6,669 SharesMarch 11, 2025 | insidertrades.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Down 18.2% in FebruaryKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) saw a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 5,830,000 shares, a decline of 18.2% from the January 31st total of 7,130,000 shares. Based on an average daily volume of 371,600 shares, the days-to-cover ratio is currently 15.7 days.March 5, 2025 | marketbeat.comKalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual MeetingMarch 3, 2025 | finance.yahoo.comKalVista Pharmaceuticals (KALV) to Release Quarterly Earnings on MondayKalVista Pharmaceuticals (NASDAQ:KALV) will be releasing earnings before the market opens on Monday, March 10, Financial Modeling Prep reports.March 3, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Paul K. Audhya Sells 2,394 SharesKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) insider Paul K. Audhya sold 2,394 shares of the business's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $10.02, for a total transaction of $23,987.88. Following the sale, the insider now owns 102,940 shares in the company, valued at $1,031,458.80. This represents a 2.27 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.February 26, 2025 | marketbeat.comPaul K. Audhya Sells 2,394 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) StockFebruary 26, 2025 | insidertrades.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of "Buy" from AnalystsShares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) have been assigned a consensus rating of "Buy" from the seven research firms that are currently covering the company, MarketBeat reports. Six analysts have rated the stock with a buy rating and one has assigned a strong buyFebruary 25, 2025 | marketbeat.comKalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual MeetingFebruary 21, 2025 | uk.finance.yahoo.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Paul K. Audhya Sells 3,125 SharesKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) insider Paul K. Audhya sold 3,125 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total value of $30,687.50. Following the sale, the insider now owns 100,334 shares of the company's stock, valued at $985,279.88. This trade represents a 3.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.February 20, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 5,104 SharesKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin L. Palleiko sold 5,104 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $50,121.28. Following the sale, the chief executive officer now directly owns 278,855 shares of the company's stock, valued at $2,738,356.10. This represents a 1.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.February 20, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Trading Up 8.7% - What's Next?KalVista Pharmaceuticals (NASDAQ:KALV) Shares Up 8.7% - Time to Buy?February 20, 2025 | marketbeat.comTD Cowen Remains a Buy on Supernus Pharmaceuticals (SUPN)February 20, 2025 | markets.businessinsider.com Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address KALV Media Mentions By Week KALV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KALV News Sentiment▼1.680.72▲Average Medical News Sentiment KALV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KALV Articles This Week▼63▲KALV Articles Average Week Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MLTX News ACAD News ALVO News TWST News AMRX News DNLI News RXRX News APLS News IBRX News BHVN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KALV) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KALV Stock Free KALV Stock Alerts